Expression of concern: Drug safety evaluation of amlodipine (Expert Opinion on Biological Therapy, (2011), 10, 5, (795-804), 10.1517/14740338.2011.585966);Drug safety evaluation of amlodipine

Expert Opinion on Drug Safety

Volumn 10, Issue 5, 2011, Pages 795-804

  Derosa, Giuseppe ^a   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

adverse events; amlodipine; antihypertensive drugs; calcium channel blockers; hypertension

Indexed keywords

ALISKIREN; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN HEXETIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROCHLOROTHIAZIDE; OLMESARTAN; RAMIPRIL; TELMISARTAN;

ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; BLOOD PRESSURE; CELL PROLIFERATION; CLINICAL EVALUATION; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; EDEMA; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOTENSION; PERIPHERAL EDEMA; SMOOTH MUSCLE FIBER;

EID: 80051962239     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1080/14740338.2018.1475450     Document Type: Erratum

References (34)

1. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17
2. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
3. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC), 2007 Guidelines for the Management of Arterial Hypertension. J Hypertens 2007;25:1105-87
4. Zanchetti A, Bond MG, Hennig M, et al. for the European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-7
5. Zanchetti A, Bond MG, Hennig M, et al. for the ELSA Investigators. Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: Further results of the European Lacidipine Study on Atherosclerosis (ELSA). J Hypertens 2004;22:1201-12
6. Simon A, Gariepy J, Moyse D, Leve nson J. Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001;103:2949-54
7. Terpstra WF, May JF, Smit AJ, et al. Effects of amlodipine and lisinopril on intima-media thickness in previously untreated, elderly hypertensive patients (the ELVERA trial). J Hypertens 2004;22:1309-16
8. Norvasc®. Package insert. Pfizer, Inc., NY, USA
9. Preston RA, Harvey P, Herfert O, et al. A randomized, placebo-controlled trial to evaluate the efficacy, safety, and pharmacodynamic interaction of coadministered amlodipine and atorvastatin in 1660 patients with concomitant hypertension and dyslipidemia: The respond trial. J Clin Pharmacol 2007;47(5):1555-69
10. Derosa G, Maffioli P. Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients. Expert Rev Cardiovasc Ther 2010;8(6):835-43
11. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-91
12. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of randomized controlled trials: Is blinding necessary? Control Clin Trials 1996;17:1-12
13. Luksa J, Josic D, Kremser M, et al. Pharmacokinetic behaviour of R-(+)- and S-(-)-amlodipine after single enantiomer administration. J Chromatogr B Biomed Sci Appl 1997;703(1-2):185-93
14. Fogari R, Mugellini A, Zoppi A, et al. Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation. J Cardiovasc Pharmacol Ther 2011;doi: 10.1177/1074248410395018
15. Fogari R, Mugellini A, Derosa G, on behalf of the CANDIA (CANdesartan and DIuretic vs Amlodipine in hypertensive patients) Study Group. Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:139-44 The study shows the non inferiority of amlodipine compared to candesartan/ hydrochlorothiazide.
16. Mengden T, Vetter H, Tousset E, Uen S. Management of patients with uncontrolled arterial hypertension-the role of electronic compliance monitoring, 24-h ambulatory blood pressure monitoring and Candesartan/HCT. BMC Cardiovasc Disord 2006;6:36
17. Fogari R, Derosa G, Lazzari P, et al. Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. AJH 2004;17:823-7
18. Gleerup G, Winther K. Decreased fibrinolytic activity and increased platelet function in hypertension. Am J Hypertens 1991;4:168S-71S
19. Ghiadoni L, Magagna A, Versari D, et al. Different effect of antihypertensive drugs on artery endothelial function. Hypertension 2003;41:1281-6
20. Mason RPO. Atheroprotective effects of long-acting dihydropyridine-type calcium channel blockers: Evidence from clinical trials and basic scientific research. Cerebrovasc Dis 2003;16(Suppl):11-17
21. Lijnen HR, Collen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 1993;22(Suppl 4):S1-14
22. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol 1993;22(Suppl 4):S1-14
23. Yamamoto K, Ozaki H, Takayasu K, et al. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hyperten Res 2011;34:325-30
24. Pitt B, Byington RP, Furberg CD, et al. for the PREVENT Investigators. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000;102:1503-10 The study shows the positive effect of amlodipine on atherosclerosis.
25. Nissen SE, Tuzcu EM, Libby P, et al. for the CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure the CAMELOT study: A randomized controlled trial. JAMA 2004;292(18):2217-26 The study compares amlodipine and enalapril on the occurrences of thrombosis.
26. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002;288(23):2981-97 The study shows the effect of amlodipine on fatal coronary heart disease or nonfatal myocardial infarction.
27. Julius S, Weber MA, Kjeldsen SE, et al. The valsartan antihypertensive long-term use evaluation (VALUE) trial outcomes in patients receiving monotherapy. Hypertension 2006;48:385-91 The study compares amlodipine and valsartan regimens.
28. Jørgensen B, Thaulow E; Coronary Angioplasty Amlodipine Restenosis Study. Effects of amlodipine on ischemia after percutaneous transluminal coronary angioplasty: Secondary results of the Coronary Angioplasty Amlodipine Restenosis (CAPARES) Study. Am Heart J 2003;145(6):1030-5
29. Leonetti G, Magnani B, Pessina AC, et al. COHORT Study Group. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002;15(11):932-40
30. Pedrinelli R, Dell'Omo G, Nuti M, et al. Heterogeneous effect of calcium antagonists on leg oedema: A comparison of amlodipine versus lercanidipine in hypertensive patients. J Hypertens 2003;21(10):1969-73
31. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30(4):587-604
32. Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): A randomised, parallel-group trial. Lancet 2011;377:312-20
33. Jorgensen B, Simonsen S, Endresen K, et al. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: Results from the Coronary Angioplasty Amlodipine Restenosis Study (CAPARES). J Am Coll Cardiol 2000;35:592-9
34. Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: Review of the evidence. Atherosclerosis 2002;165:191-9